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BACKGROUND: KCNJ11 mutations cause permanent neonatal diabetes through
pancreatic ATP-sensitive potassium channel activation. 90% of patients successfully
transfer from insulin to oral sulfonylureas with excellent initial glycaemic control;
however, whether this control is maintained in the long term is unclear. Sulfonylurea
failure is seen in about 44% of people with type 2 diabetes after 5 years of treatment.
Therefore, we did a 10-year multicentre follow-up study of a large international cohort
of patients with KCNJ11 permanent neonatal diabetes to address the key questions
relating to long-term efficacy and safety of sulfonylureas in these patients.
METHODS: In this multicentre, international cohort study, all patients diagnosed with
KCNJ11 permanent neonatal diabetes at five laboratories in Exeter (UK), Rome (Italy),
Bergen (Norway), Paris (France), and Krakow (Poland), who transferred from insulin
to oral sulfonylureas before Nov 30, 2006, were eligible for inclusion. Clinicians
collected clinical characteristics and annual data relating to glycaemic control,
sulfonylurea dose, severe hypoglycaemia, side-effects, diabetes complications, and
growth. The main outcomes of interest were sulfonylurea failure, defined as
permanent reintroduction of daily insulin, and metabolic control, specifically HbA and
sulfonylurea dose. Neurological features associated with KCNJ11 permanent neonatal
diabetes were also assessed. This study is registered with ClinicalTrials.gov, number
NCT02624817.
FINDINGS: 90 patients were identified as being eligible for inclusion and 81 were
enrolled in the study and provided long-term (>5·5 years cut-off) outcome data.
Median follow-up duration for the whole cohort was 10·2 years (IQR 9·3-10·8). At
most recent follow-up (between Dec 1, 2012, and Oct 4, 2016), 75 (93%) of 81
participants remained on sulfonylurea therapy alone. Excellent glycaemic control was
maintained for patients for whom we had paired data on HbA and sulfonylurea at all
time points (ie, pre-transfer [for HbA], year 1, and most recent follow-up; n=64)-
median HbA was 8·1% (IQR 7·2-9·2; 65·0 mmol/mol [55·2-77·1]) before transfer to
sulfonylureas, 5·9% (5·4-6·5; 41·0 mmol/mol [35·5-47·5]; p<0·0001 vs pre-transfer) at
1 year, and 6·4% (5·9-7·3; 46·4 mmol/mol [41·0-56·3]; p<0·0001 vs year 1) at most
recent follow-up (median 10·3 years [IQR 9·2-10·9]). In the same patients, median
sulfonylurea dose at 1 year was 0·30 mg/kg per day (0·14-0·53) and at most recent
follow-up visit was 0·23 mg/kg per day (0·12-0·41; p=0·03). No reports of severe
hypoglycaemia were recorded in 809 patient-years of follow-up for the whole cohort
(n=81). 11 (14%) patients reported mild, transient side-effects, but did not need to
stop sulfonylurea therapy. Seven (9%) patients had microvascular complications;
these patients had been taking insulin longer than those without complications
(median age at transfer to sulfonylureas 20·5 years [IQR 10·5-24·0] vs 4·1 years
[1·3-10·2]; p=0·0005). Initial improvement was noted following transfer to
sulfonylureas in 18 (47%) of 38 patients with CNS features. After long-term therapy
with sulfonylureas, CNS features were seen in 52 (64%) of 81 patients.
INTERPRETATION: High-dose sulfonylurea therapy is an appropriate treatment for
patients with KCNJ11 permanent neonatal diabetes from diagnosis. This therapy is
safe and highly effective, maintaining excellent glycaemic control for at least 10
years.
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